A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer

NCT07446387 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer (CRC)

Interventions

DRUG: Iparomlimab and tuvonralimab

Sponsor

Jiangsu Cancer Institute & Hospital